State Street Corporation 13D and 13G filings for Viking Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-10-18 12:26 pm Sale |
2024-09-30 | 13G | Viking Therapeutics, Inc. VKTX |
STATE STREET CORP STT |
4,666,157 4.200% |
-1,066,833 (-18.61%) |
Filing |
| 2024-01-24 1:24 pm Purchase |
2023-12-31 | 13G | Viking Therapeutics, Inc. VKTX |
STATE STREET CORP STT |
5,732,990 5.730% |
5,486,148 (+2222.53%) |
Filing |
| 2023-02-03 3:36 pm Sale |
2022-12-31 | 13G | Viking Therapeutics, Inc. VKTX |
STATE STREET CORP STT |
246,842 0.320% |
-3,878,725 (-94.02%) |
Filing |
| 2022-02-11 9:23 pm Sale |
2021-12-31 | 13G | Viking Therapeutics, Inc. VKTX |
STATE STREET CORP STT |
4,125,567 5.270% |
-946,989 (-18.67%) |
Filing |
| 2021-02-11 4:17 pm Purchase |
2020-12-31 | 13G | Viking Therapeutics, Inc. VKTX |
STATE STREET CORP STT |
5,072,556 6.950% |
1,462,294 (+40.50%) |
Filing |